"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
(See BOXED WARNINGS.) Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycoside antibiotics cross the placenta, and there have been several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Serious side effects to mother, fetus, or new born have not been reported in the treatment of pregnant women with other aminoglycosides. Animal reproduction studies conducted on rats and rabbits did not reveal evidence of impaired fertility or harm to the fetus due to gentamicin (gentamicin injection pediatric) sulfate.
It is not known whether gentamicin (gentamicin injection pediatric) sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. If gentamicin (gentamicin injection pediatric) is used during pregnancy or if the patient becomes pregnant while taking gentamicin (gentamicin injection pediatric) , she should be apprised of the potential hazard to the fetus.
Preserved Gentamicin (gentamicin injection pediatric) Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes incertain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Prescribing Gentamicin (gentamicin injection pediatric) Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Neurotoxic and nephrotoxic antibiotics may be almost completely absorbed from body surfaces (except the urinary bladder) after local irrigation and after topical application during surgical procedures. The potential toxic effects of antibiotics administered in this fashion (neuromuscular blockade, respiratory paralysis, oto- and nephrotoxicity) should be considered (see BOXED WARNINGS).
Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.
Neuromuscular blockade and respiratory paralysis have been reported in the cat receiving high doses (40 mg/kg) of gentamicin (gentamicin injection pediatric) . The possibility of these phenomena occurring in man should be considered if aminoglycosides are administered by any route to patients receiving anesthetics, or to patients receiving neuromuscular blocking agents, such as succinylcholine, tubocurarine or decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood.If neuromuscular blockade occurs, calcium salts may reverse it.
Aminoglycosides should be used with caution in patients with neuromuscular disorders, such asmyastheniagravis, since these drugs may aggravate muscle weakness because of their potential curare-like effects on the neuromuscular junction. During or following gentamic in therapy, paresthesias, tetany, positive Chvostek and Trousseau signs, and mental confusion have been described in patients with hypomagnesemia, hypocalcemia, and hypokalemia. When this has occurred in infants, tetany and muscle weakness have been described. Both adults and infants required appropriate corrective electrolyte therapy.
A Fanconi-like syndrome, with amino-aciduria andmetabolicacidosis,hasbeenreportedinsome adults and infants being given gentamicin (gentamicin injection pediatric) injections.
Cross-allergenicityamongaminoglycosideshas been demonstrated.
Patients should be well hydrated during treatment.
Although the in vitro mixing of gentamicin (gentamicin injection pediatric) and carbenicillin results in a rapid and significant inactivation of gentamicin (gentamicin injection pediatric) , this interaction has not been demonstrated in patients with normal renal function who received both drugs by different routes of administration. A reductionin gentamicin (gentamicin injection pediatric) serum half-life has been reported in patients with severe renal impairment receiving carbenicillin concomitantly with gentamicin (gentamicin injection pediatric) .
Treatment with gentamicin (gentamicin injection pediatric) may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy is indicated.
Do not administer unless solution is clear and package undamaged.
Pregnancy Category D
See WARNINGS section.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 6/24/2008
Additional Gentamicin Pediatric Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.